Stay updated on Pyrotinib Adjuvant Study in HER-2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Adjuvant Study in HER-2+ Breast Cancer Clinical Trial page.

Latest updates to the Pyrotinib Adjuvant Study in HER-2+ Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision history updated to include v3.3.3; the HHS Vulnerability Disclosure link and revision v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe record history now shows a new revision entry v3.3.2, replacing the previous v3.2.0 entry.SummaryDifference0.1%

- Check39 days agoChange DetectedA government funding notice appears, warning that information may not be up to date and that transactions may not be processed, with links to cc.nih.gov and opm.gov for status updates.SummaryDifference0.8%

- Check53 days agoChange DetectedThe history shows multiple versions with updates to study status and recruitment across several dates, including a later entry in 2025. This indicates ongoing updates to the trial record.SummaryDifference0.1%

- Check82 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference13%

- Check89 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

Stay in the know with updates to Pyrotinib Adjuvant Study in HER-2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Adjuvant Study in HER-2+ Breast Cancer Clinical Trial page.